Apply to trial NCT07077486

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 4Drug trial

Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease

Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening